Indications |
Oral Uncomplicated lower urinary tract infections Adult: 1-2 g daily as a single or 2 divided doses. Child: >6 yr: 500 mg bid; 1-6 yr: 250 mg bid; <1 yr: 25 mg/kg daily in divided doses.
Oral Skin and skin structure infections Adult: 1 g/day in single or divided doses. Child: 30 mg/kg/day in equally divided doses every 12 hr.
Oral Pharyngitis Adult: For treatment of group A β-haemolytic streptococcal pharyngitis and tonsillitis: 1 g/day in single or divided doses for 10 days. Child: 30 mg/kg/day in equally divided doses every 12 hr for at least 10 days.
Oral Tonsillitis Adult: For treatment of group A β-haemolytic streptococcal pharyngitis and tonsillitis: 1 g/day in single or divided doses for 10 days. Child: 30 mg/kg/day in equally divided doses every 12 hr for at least 10 days.
Special Populations: In infections with beta-hemolytic streptococci, treatment should be continued for at least 10 days. Renal impairment: Dose reduction based on creatinine clearance. |
||||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity to cephalosporins. | ||||||||||||||||||||||||||||||||
Warnings / Precautions |
Impaired renal function; pregnancy and lactation. | ||||||||||||||||||||||||||||||||
Adverse Reactions |
Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida. Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis. |
||||||||||||||||||||||||||||||||
Drug Interactions |
Prothrombin time prolonged; bleeding may occur when taken with anticoagulants. Decreased elimination with probenecid. See Below for More cefadroxil Drug Interactions |
||||||||||||||||||||||||||||||||
Lab Interactions |
False-positive results for direct Coombs' test and urine sugar (Benedict's, Fehling's or other reagents but not with enzyme-based methods). Interferes with Jaffe method of measuring creatinine. | ||||||||||||||||||||||||||||||||
Mechanism of Actions |
Cefadroxil binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Cefadroxil is not active against Proteus, Pseudomonas, Enterobacter, Morganella, Serratia and Listeria monocytogenes. Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 1.5-2 hr. Distribution: Body tissues and fluids (wide); crosses the placenta and enters breast milk. Protein-binding: 20%. Excretion: Via urine by glomerular filtration and tubular secretion (90% as unchanged); 1.5 hr (elimination half-life), prolonged in renal impairment. Removed by dialysis. |
||||||||||||||||||||||||||||||||
Administration |
May be taken with or without food. (May be taken w/ meals to reduce GI discomfort.) |
||||||||||||||||||||||||||||||||
Storage Conditions |
Oral: Store at 15-30°C. | ||||||||||||||||||||||||||||||||
ATC Classification |
J01DB05 - cefadroxil ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections. | ||||||||||||||||||||||||||||||||
Storage |
Oral: Store at 15-30°C. | ||||||||||||||||||||||||||||||||
Available As |
|
Cefadroxil
Post Review about Cefadroxil Click here to cancel reply.
Cefadroxil is used in following diseases
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.